Dr. Reddy's Laboratories Limited (RDY)
After hours:
| Previous Close | 69.30 |
| Open | 69.18 |
| Bid | 68.22 x 1000 |
| Ask | 68.77 x 900 |
| Day's Range | 68.17 - 69.09 |
| 52 Week Range | 53.88 - 77.72 |
| Volume | |
| Avg. Volume | 199,917 |
| Market Cap | 11.57B |
| Beta (5Y Monthly) | 0.34 |
| PE Ratio (TTM) | 17.02 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.49 (0.71%) |
| Ex-Dividend Date | Jul 07, 2023 |
| 1y Target Est | N/A |
- Business Wire
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
HYDERABAD, India, May 07, 2024--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024.
- Business Wire
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
HYDERABAD, India, May 03, 2024--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
- GlobeNewswire
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
